Improvements in cancer survival are usually assessed by comparing survival in grouped years of diagnosis. To enhance analyses of survival trends, Mariotto and colleagues presented the joinpoint survival model webtool (JPSurv) that analyzes survival data by single year of diagnosis and estimates changes in survival trends and year-over-year trend measures. The authors apply JPSurv to relative survival data for individuals diagnosed with female breast cancer, melanoma cancer, Non-Hodgkin Lymphoma (NHL) and Chronic Myeloid Leukemia (CML) between 1975–2015 in the Surveillance, Epidemiology, and End Results (SEER) Program. The greatest increases in trends for distant melanoma, NHL and CML coincided with the introduction of novel treatments, demonstrating the value of JPSurv for estimating and interpreting cancer survival trends. The JPSurv webtool provides a suite of estimates for analyzing trends in cancer survival that complement traditional descriptive survival analyses.

This study by Zhao and colleagues documented racial disparities in survival among patients with...

You do not currently have access to this content.